Zydus Lifesciences inches up as its arm receives USFDA`s approval for Levothyroxine Sodium for Injection
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Zydus Lifesciences is currently trading at Rs. 402.65, up by 0.85 points or 0.21% from its previous closing of Rs. 401.80 on the BSE.
The scrip opened at Rs. 402.10 and has touched a high and low of Rs. 404.80 and Rs. 402.10 respectively. So far 1015 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 487.00 on 03-Jan-2022 and a 52 week low of Rs. 319.40 on 11-May-2022.
Last one week high and low of the scrip stood at Rs. 404.80 and Rs. 390.10 respectively. The current market cap of the company is Rs. 40670.36 crore.
The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 15.53% and 9.49% respectively.
Zydus Lifesciences’ U.S. subsidiary -- Zydus Pharmaceuticals (USA) Inc. has received tentative approval from the United States Food and Drug Administration (USFDA) to market Levothyroxine Sodium for injection, 100 mcg/vial, 200 mcg/vial, and 500 mcg/vial (USRLD: Levothyroxine Sodium injection manufactured by Fresenius Kabi USA, LLC).
Levothyroxine Sodium injection is indicated for the treatment of myxedema coma. The drug will be manufactured at the group’s injectable manufacturing facility at Jarod, near Vadodara, India. Levothyroxine Sodium injection had annual sales of $45.2 million in the United States according to IQVIA data (IQVIA MAT Sep 2022). The group now has 334 approvals and has so far filed over 431 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.
